Should I buy Colgate-Palmolive (CL) stock or is it too late?
⭐ The most reliable of them, either direction: Evercore ISI Group — 69% of its targets hit on this sector (129 calls tested). It aims for $101 (+12 %), call made on August 4, 2026, maturing on August 4, 2027 (71 d ago).
Firm-by-firm track record on Colgate-Palmolive
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| B of A Securities | 67 % | +9.0 % | 6 | $102 +13% |
| Morgan Stanley | 81 % | +8.0 % | 16 | $95 +6% |
| Citigroup | 60 % | +7.1 % | 10 | $110 +22% |
| Wells Fargo | 71 % | +7.0 % | 7 | $90 +0% |
| Deutsche Bank | 60 % | +5.1 % | 10 | $98 +9% |
| JP Morgan | 53 % | +3.7 % | 15 | $103 +15% |
| UBS | 61 % | +3.3 % | 18 | $109 +21% |
| Stifel | 83 % | +13.1 % | 6 | — |
✅ Reasons to believe
- 67% of analysts rate it a buy (Buy consensus, 12 ratings) — a sign of market conviction.
- Median price target $98, i.e. +9% from the current price ($90).
- Pays a dividend (2.3% yield) — regular income on top of potential upside.
⚠️ Reasons to hesitate
- Even the most reliable firm on CL, Barclays (100% hit rate, 2 scored calls), only targets $87 (call made on July 21, 2026, maturing on July 21, 2027) (-3%) in its most recent call, and $80 (call made on November 4, 2025, maturing on November 4, 2026) (-11%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 12 ratings, 4 are neutral.
- High valuation (P/E ~35): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on CL
Median target $98 (+9%) · 12 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Colgate-Palmolive now?
We won't decide for you. The facts: 67% of analysts rate it a buy, median target $98 (+9%), and Barclays (most reliable on CL, 100%) targets $87. Weigh that against valuation (P/E ~35). This is not personalized advice.
Is it too late to invest in Colgate-Palmolive?
Not according to analysts: the median target ($98) is still +9% above the current price ($90) (most reliable on CL: Barclays, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Colgate-Palmolive still worth investing in?
It depends on the gap between the price ($90) and its estimated value: analysts target $98 on median (+9%), with 67% buys (most reliable on CL: Barclays, 100%). Cross-check with their real reliability on CL and the cautions above. Information, not advice.
What's the main risk in buying CL?
Even the most reliable firm on CL, Barclays (100% hit rate, 2 scored calls), only targets $87 (call made on July 21, 2026, maturing on July 21, 2027) (-3%) in its most recent call, and $80 (call made on November 4, 2025, maturing on November 4, 2026) (-11%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Colgate-Palmolive profile (consensus, analyst reliability, price target, performance).